Parkinson’s Progression Markers Initiative

Select Preliminary Baseline Data for 90% of Cohort Recruited is Presented at AAN

PPMI senior leadership presented PPMI data collected so far at the American Academy of Neurology’s 75th annual meeting. The poster used baseline data to give a preliminary sense of the characteristics of the PPMI cohort. The poster also highlights CSF acquisition success rates in PPMI and data from baseline DaTSCANs.

Researchers Publish First Paper Using PPMI Data

Daniel Weintraub, MD, and a team at the University of Pennsylvania publish the first paper using PPMI data demonstrating that Parkinson's itself does not confer a higher risk for ICDs, supporting other research that suggests the high prevalence of ICDs in people with PD is related to Parkinson's medications, and not the disease itself.

Screening for impulse control symptoms in patients with de novo Parkinson disease: A case-control study (Neurology)

Dr. Daniel Weintraub analyzes the QUIP data from the PPMI database to assess frequencies of impulse disorders in PD patients and comparing this to control participants. Through his analysis using multivariable models, a diagnosis of PD was not associated with symptoms of any impulse control or related behavior (p ≥ 0.10 in all cases).

New page listing ongoing analyses with PPMI data

A new page has been added to the site to highlight all of the proposed analyses submitted by individuals who sign up to access the data. Individuals who are interested in using PPMI data can use this resource to better understand potential uses of the data, identify collaborators, and spark new research ideas.

MDS Presentation on PPMI- Frequency of Impulse Control Disorders in PD vs. Controls

These results suggest that PD itself does not confer an increased risk for development of ICD symptoms and related behaviors, which reinforces the reported association between PD medications and ICDs in PD. Given that approximately 20% of untreated PD patients screen positive for ICD or related symptoms, long-term follow-up of the PPMI cohort will determine if such patients are at increased risk of ICD development when PD medications are initiated.

Moderated stats forum addresses questions on PPMI data

A statistics forum has been created to help investigators who are interested in accessing or who have accessed the PPMI database find additional information about the dataset.

Upcoming presentations on PPMI at The Movement Disorders Society International Congress

Five abstracts will be presented at MDS in mid-June. Learn more about the topics that will be covered.

Clinical Data and Biospecimens available for over 200 subjects

With over 200 PPMI subjects enrolled, the clinical data and biospecimens is robust and available in real time. The goal of PPMI is to validate biomarkers of PD progression. The cornerstone of this study is making the data and samples collected available to the scientific community.

Statistics about data downloads and specimen requests on PPMI-info.org

A new page has been added to the website to show the number of data downloads and specimen requests, as well as where people who download the data are from globally and by sector.

Monthly Archives

Tag Archive | "Data"

Select Preliminary Baseline Data for 90% of Cohort Recruited is Presented at AAN

Researchers Publish First Paper Using PPMI Data

Screening for impulse control symptoms in patients with de novo Parkinson disease: A case-control study (Neurology)

New page listing ongoing analyses with PPMI data

MDS Presentation on PPMI- Frequency of Impulse Control Disorders in PD vs. Controls

Moderated stats forum addresses questions on PPMI data

Upcoming presentations on PPMI at The Movement Disorders Society International Congress

Clinical Data and Biospecimens available for over 200 subjects

Statistics about data downloads and specimen requests on PPMI-info.org